Therapeutic Effect of Yu Melody Relaxation Training Combined with Jianpi Jieyu Decoction in Insomnia Patients: A Randomized Controlled Trial.
10.1007/s11655-024-3923-1
- Author:
Hao-Yu PANG
1
;
Xu CHEN
2
;
Ling-Yun XI
2
;
Qian-Lin JIA
2
;
Yang BAI
2
;
Jing CAO
1
;
Xia HONG
3
Author Information
1. Department of Neurology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China.
2. Graduate School, Beijing University of Chinese Medicine, Beijing, 100029, China.
3. Department of Neurology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China. 970236538@qq.com.
- Publication Type:Randomized Controlled Trial
- Keywords:
Chinese medicine;
Yu Melody relaxation training;
five-element music;
insomnia disorders;
relaxation therapy
- MeSH:
Humans;
Sleep Initiation and Maintenance Disorders/drug therapy*;
Drugs, Chinese Herbal/therapeutic use*;
Male;
Female;
Relaxation Therapy/methods*;
Middle Aged;
Adult;
Treatment Outcome;
Combined Modality Therapy
- From:
Chinese journal of integrative medicine
2025;31(4):291-298
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To evaluate the therapeutic effect of Yu Melody relaxation training (YMRT) combined with Jianpi Jieyu Decoction (JJD) in treating patients with insomnia disorders (ID).
METHODS:In this randomized controlled study, 94 ID patients were included from Xiyuan Hospital, China Academy of Chinese Medical Sciences from September 2022 to January 2024. They were randomly assigned to the YMRT group (47 cases, YMRT plus JJD) and the control group (47 cases, oral JJD) using a random number table. Both treatment administrations lasted for 4 weeks, with a 2-week follow-up. The primary outcome was change in Insomnia Severity Index (ISI) scores from baseline to 4 weeks of intervention. Secondary outcomes included ISI response at week 4, as well as ISI, Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder 7-item (GAD-7) scores at baseline and weeks 1, 2, 3, 4, and 6. Additionally, Pittsburgh Sleep Quality Index (PSQI) scores were evaluated at baseline and weeks 4 and 6. Adverse events (AEs) were recorded and compared between groups.
RESULTS:Five patients in each group did not complete the protocol requirements. The overall dropout rate was 10.64%. The full analysis set included all 47 cases in each group. The ISI score decreased significantly at week 4 from baseline in the YMRT group compared with the control group, with a between-group difference of -3.2 points [95% confidence interval (CI): -5.08 to -1.34; P<0.05]. The ISI response at week 4 in the YMRT group was significantly higher than that in the control group (85.11% vs. 51.06%), with a between-group difference of 34.05% (95% CI: 13.77% to 50.97%; P<0.05). At week 6, the YMRT group demonstrated greater reductions from baseline than the control group, with between-group differences of -2.1 points (-95% CI: -3.49 to -0.64; P<0.05) for PHQ-9 scores, -3.5 points (95% CI: -5.21 to -1.85; P<0.05) for PSQI scores, and -1.9 points (95% CI: -3.47 to -0.28; P<0.05) for GAD-7 scores. Moreover, at weeks 4 and 6, the ISI and PSQI scores in the YMRT group were significantly lower than those in the control group (P<0.05); and at week 6, the PHQ-9 score in the YMRT group was significantly lower (P<0.05). There was no significant difference in the incidence rates of AEs between the two groups (8.51% vs. 4.26%, P>0.05).
CONCLUSIONS:YMRT combined with oral JJD could improve sleep quality and alleviate depressive and anxiety symptoms in patients with ID. This combined therapy was effective and safe, and its effect was superior to oral JJD alone. (Registration No. ChiCTR2200063884).
